September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing
Author Affiliations & Notes
  • Amit Meshi
    Ophthalmology, Meir Medical Center, Tel Aviv, Israel
  • Ori Segal
    Ophthalmology, Meir Medical Center, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Amit Meshi, None; Ori Segal, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 551. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Amit Meshi, Ori Segal; Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Invest. Ophthalmol. Vis. Sci. 2016;57(12):551.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of bevacizumab dosing every 2 weeks in patients with neovascular age-related macular degeneration (nvAMD) refractory to monthly dosing.

Methods : A retrospective chart review of nvAMD patients unresponsive to conventional monthly dosing of anti-vascular endothelial growth factor (VEGF) therapies which received one course of 3-4 intravitreal bevacizumab injections every 2 weeks.

Results : Twenty seven eyes of 24 patients (13 females) were identified. Mean (±SD) age was 82.08 ± 6.85 years. All patients failed monthly bevacizumab, 17 patients (70.8%) also failed monthly ranibizumab and 3 patients (12.5%) were unresponsive to all three anti-VEGF drugs. The mean (±SD) number of prior anti-VEGF injections was 21.33 ± 6.8. Bevacizumab injections during the treatment course were administered at a mean (±SD) interval of 15.4 ± 1.37 days. Patients were examined 5.13 ± 1.67 weeks (±SD) after the last injection. The mean (±SD) logarithm of the minimum angle of resolution (logMAR) visual acuity did not change significantly between baseline (0.72 ± 0.59) and follow-up (0.76 ± 0.66, P = 0.56). The objective spectral-domain optical coherence tomography (SD-OCT) parameters (mean central macular thickness and mean macular volume) did not change significantly between baseline and follow-up (P > 0.05). Six eyes (22.2%) showed anatomic improvement on SD-OCT scans, while 19 eyes (70.4%) remained stable.

Conclusions : Biweekly bevacizumab dosing may cause anatomic benefit in some chronic cases of nvAMD refractory to anti-VEGF monthly dosing.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×